v3.25.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Cash flows from operating activities    
Net loss $ (31,347) $ (21,617)
Adjustments to reconcile net loss to net cash used in operating activities    
Depreciation and amortization expense 443 730
Stock-based compensation - Lucid Diagnostics Inc. 2018 Equity Plan 2,092 1,850
Stock-based compensation - PAVmed Inc. 2014 Equity Plan 82 285
Change in fair value - Senior Secured Convertible Note 7,638 (890)
Debt extinguishment loss - Senior Secured Convertible Note 681
Amortization of common stock payment for vendor service agreement 147 113
Changes in operating assets and liabilities:    
Accounts receivable (328) (115)
Prepaid expenses and other current assets (942) 625
Accounts payable (408) (243)
Accrued expenses and other current liabilities (407) (1,114)
Due To: PAVmed Inc. - operating expenses, employee related costs, MSA Fee 16 (4,399)
Net cash flows used in operating activities (23,014) (24,094)
Cash flows from investing activities    
Purchase of equipment (118) (37)
Net cash flows used in investing activities (118) (37)
Cash flows from financing activities    
Proceeds – issue of preferred stock 29,798
Proceeds – issue of common stock - Registered Direct Offering, net of fees 14,935
Proceeds – issue of common stock - Confidentially Marketed Public Offering, net of fees 16,174
Proceeds – issue of Senior Secured Convertible Notes 360
Proceeds – issue of common stock – At-The-Market Facility 274
Proceeds – exercise of stock options 13 4
Proceeds – issue common stock – Employee Stock Purchase Plan 141 353
Net cash flows provided by financing activities 31,897 30,155
Net increase in cash 8,765 6,024
Cash, beginning of period 22,358 18,896
Cash, end of period $ 31,123 $ 24,920